Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$20.28
-0.76-3.61%
At close: -
$20.28
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Enliven Therapeutics Analyst Ratings and Price Targets | NASDAQ:ELVN | Benzinga
Enliven Therapeutics Inc has a consensus price target of $36 based on the ratings of 7 analysts. The high is $42 issued by BTIG on December 13, 2024. The low is $27 issued by Jefferies on March 29, 2023. The 3 most-recent analyst ratings were released by BTIG, Baird, and Jones Trading on December 13, 2024, November 15, 2024, and October 31, 2024, respectively. With an average price target of $39.33 between BTIG, Baird, and Jones Trading, there's an implied 93.95% upside for Enliven Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BTIG
Baird
Jones Trading
HC Wainwright & Co.
Mizuho
1calculated from analyst ratings
Analyst Ratings for Enliven Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/13/2024 | Buy Now | 107.1% | BTIG | Justin Zelin | → $42 | Initiates | → Buy | Get Alert |
| 11/15/2024 | Buy Now | 97.24% | Baird | Colleen Kusy | $32 → $40 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 77.51% | Jones Trading | Soumit Roy | → $36 | Initiates | → Buy | Get Alert |
| 10/01/2024 | Buy Now | 82.45% | HC Wainwright & Co. | Robert Burns | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | 82.45% | HC Wainwright & Co. | Robert Burns | → $37 | Initiates | → Buy | Get Alert |
| 06/11/2024 | Buy Now | 57.79% | Baird | Colleen Kusy | → $32 | Initiates | → Outperform | Get Alert |
| 04/09/2024 | Buy Now | 67.65% | Mizuho | Salim Syed | → $34 | Initiates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 33.14% | Jefferies | Eun Yang | → $27 | Initiates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | — | TD Cowen | Phil Nadeau | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Enliven Therapeutics (ELVN) stock?
The latest price target for Enliven Therapeutics (NASDAQ:ELVN) was reported by BTIG on December 13, 2024. The analyst firm set a price target for $42.00 expecting ELVN to rise to within 12 months (a possible 107.10% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enliven Therapeutics (ELVN)?
The latest analyst rating for Enliven Therapeutics (NASDAQ:ELVN) was provided by BTIG, and Enliven Therapeutics initiated their buy rating.
When was the last upgrade for Enliven Therapeutics (ELVN)?
There is no last upgrade for Enliven Therapeutics
When was the last downgrade for Enliven Therapeutics (ELVN)?
There is no last downgrade for Enliven Therapeutics.
When is the next analyst rating going to be posted or updated for Enliven Therapeutics (ELVN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enliven Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enliven Therapeutics was filed on December 13, 2024 so you should expect the next rating to be made available sometime around December 13, 2025.
Is the Analyst Rating Enliven Therapeutics (ELVN) correct?
While ratings are subjective and will change, the latest Enliven Therapeutics (ELVN) rating was a initiated with a price target of $0.00 to $42.00. The current price Enliven Therapeutics (ELVN) is trading at is $20.28, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.